For Healthcare Providers


At Pairnomix, we ensure that physicians, like you, play a prominent role in our process, because we know only you can decide what’s best for your patient.

That means we send our personalized reports directly to you, so you can explain and discuss the contents with your patient. Our hope is that this information empowers you to make better-informed healthcare decisions.

We’re excited about the opportunity to work with you. In the meantime, please visit our Fact Sheets page, which provides additional information about the genetics field for you patient.

  • 1. Provider FAQ
Expand All | Collapse All
  • 1. If I decide that a Pairnomix personalized genetic assessment is right for my patient, how do I order the service?
     

    Only you, the physician, can order Pairnomix services. To do this, you will need to fill out and sign the Pairnomix Order Form. This document can be provided to physicians through an email request at info@pairnomix.com.

  • 2. After I prescribe Pairnomix services, what are my responsibilities?
     

    Pairnomix works with you to provide genetic research services for your patients. We respect the relationship you have these individuals, so we involve you in every step of the process.

    After ordering Pairnomix services, you assume the following responsibilities:

    1. Providing your patient’s sequencing report and a copy of their medical record.

    Pairnomix requires the provision of such documents through physicians like you to ensure the completeness and integrity of the data.

    2. Receiving informational reports and communicating their content to your patient.

    Pairnomix releases its informational reports (the first after your patient’s mutation has been characterized and the second after drug screening studies) directly to you, the physician. We do this because only qualified physicians, like you, can make treatment decisions for patients. You are in the best position to interpret the information within the report, share it with your patient, and use it as you deem appropriate to inform clinical care.

  • 3. Do I need to have a deep understanding of genetics to order Pairnomix services?
     

    No. We do not believe having a deep understanding of genetics is a prerequisite for ordering Pairnomix services. Pairnomix Patient Advocates are available to speak with you to aid in your understanding of both the research studies and the data presented within the informational reports. However, it is your responsibility to use the findings as you see fit and determine the best course of treatment for your patient.

  • 4. Who decides the type of model to be generated and drugs to be tested?
     

    Our scientific team has significant experience both in clinical and laboratory-based sciences.

    Members of this team help determine the best model to create out of all available options. While they take multiple factors into consideration, the functionality of the gene dictates the type model that is best suited for interrogation of the mutation and its functional consequences. The scientific team also helps determine the specific drugs to be tested.

    Our scientific advisory board oversees this process and makes the final decision on what model will be generated and which drugs will be tested.

  • 5. Who carries out the research?
     

    Pairnomix works with select contract research organizations (CROs), academic labs, and other subcontractors with expertise in genetic modeling and drug screening.

  • 6. How do you ensure the quality of the research?
     

    Our research is therefore carefully planned and overseen by experts on our scientific advisory board, and it is performed with rigor and integrity. As quality research takes time to complete, we are currently targeting a timeline of 6 months, though it may take longer.

  • 7. What information is included in the informational report?
     

    We will provide you with two informational reports. The first, provided after mutation characterization, details how the normal molecular processes are disrupted by the mutation. The second, provided after drug screening, gives information on which drugs improve the dysfunction associated with the mutation.

  • 8. How do I know if this service is right for my patient?
     
    • Your patient’s condition has a genetic cause as determined by genetic testing, and that data is available to you in original form.
    • Your patient’s condition was diagnosed by a specialist and is not well managed by medication.

    Please note that our initial work is in the epilepsy and seizure disorder settings, but we will also offer our services to patients with other neurological or neuromuscular conditions that meet the above criteria.

    With this in mind, we believe our services are most indicated for patients who have a causal mutation that is poorly understood—simply because it may be difficult to know how best to care for these individuals.

    It is your decision to determine whether Pairnomix services are appropriate. As the patient’s physician, you are in the best position to determine if personalized genetic research could contribute learnings of value.

  • 9. Who determines what actions should be taken based on the model's results?
     

    Pairnomix does not engage in the practice of medicine. As the physician, and the only person qualified to treat your patient, it is your responsibility to interpret the findings presented in the informational reports and to determine the best course of treatment.

  • 10. What's the likelihood that Pairnomix services will help my patient?
     

    As a company that performs research on mutations for which there is little to no existing knowledge, we won’t know upfront what we will uncover throughout the course of our work.

    There have been a number of proof of concept studies in which mutation modeling and drug screening were shown to improve the clinical management of patients who have these specific mutations. While we cannot guarantee these results in our own cases, we do believe we can achieve some degree of learning that we can relay back to you about your patient’s mutation.